

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2025, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
ATOPIC DERMATITIS	Adbry Autoinjector (tralokinumab)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ANGIOTENSIN MODULATORS (ARB COMBINATIONS)	Entresto Sprinkle (sacubitril and valsartan)
ANTICHOLINERGICS & COPD AGENTS	Ohtuvayre (ensifentrine)
ANTICONVULSANTS (ADJUVANTS)	Vigafyde (vigabatrin)
ANTINEOPLASTICS	Retevmo (selpercatinib)
ANTINEOPLASTICS	Voranigo (vorasidenib)
BILE SALTS	Iqirvo (elafibranor)
BILE SALTS	Livdelzi (seladelpar lysine)
ERYTHROPOIESIS STIMULATING PROTEINS	Vafseo (vadadustat)
IMMUNE GLOBULINS	Alyglo (immune globulin)
SKELETAL MUSCLE RELAXANTS	Tanlor (methocarbamol)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



An Asterisk (*) denotes a new class added to the Preferred Drug List (PDL).

PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
ACNE AGENTS	adapalene gel; adapalene gel pump	X	
	benzoyl peroxide gel (generic Onexton); clindamycin phosphate; isotretinoin capsule; sodium w/sulfur suspension 10-5%		X
ANALGESICS/ANESTHETICS	lidocaine-prilocaine cream	X	
	DermacinRx Lidocan; Lidocan II, III, IV, V; Tridacaine II, III		X
ANALGESICS, OPIOIDS	Xtampza ER capsule	X	
ANDROGENIC AGENTS	testosterone pump; testosterone gel pump	X	
ANTIBIOTICS	Cleocin cream; Nuvessa gel; vancomycin solution	X	
	Clindesse cream; Firvanq solution; nitrofurantoin suspension		X
ANTICONVULSANTS	Trileptal suspension	X	
	oxcarbazepine suspension		X
ANTIDEPRESSANTS	vilazodone tablet	X	
	citalopram capsule; sertraline capsule; Viibryd tablet		X
ANTIEMETICS	Diclegis DR tablet	X	
ANTIFUNGALS	econazole cream; ketoconazole cream	X	
	clotrimazole solution NDC 50228-0502-61; griseofulvin suspension; Micotrin AC Cream; Mycozyl cream; Mycozyl powder;		X

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
ANTIMIGRAINE AGENTS, CGRP ACUTE TREATMENT	Ubrelyv tablet	X	
ANTIPARASITICS (TOPICAL)	Vanalice gel	X	
ANTIPARKINSONS AGENTS	pramipexole tablet	X	
ANTIPSORIATICS (TOPICAL)*	calcipotriene cream; Enstilar foam; Taclonex ointment; Taclonex suspension	X	
ANTIVIRALS - ANTI-HERPETIC AGENTS	famciclovir tablet	X	
ATOPIC DERMATITIS	Eucrisa ointment	X	
BETA BLOCKERS, ANTIANGINALS & SINUS NODE AGENTS	Hemangeol solution	X	
BONE RESORPTION/SUPPRESSION & RELATED AGENTS	Forteo injection; raloxifene tablet	X	
BPH AGENTS	dutasteride capsule	X	
BRONCHODILATORS, BETA AGONIST	albuterol ER tablet		X
CEPHALOSPORINS AND RELATED ANTIBIOTICS	cefixime capsule	X	
	amoxicillin/clavulanate ER tablet		X
COLONY STIMULATING FACTORS	Fulphila injection	X	
	Fynetra injection; Stimufend injection		X
CYSTIC FIBROSIS AGENTS	Pulmozyme inhalation solution	X	
CYTOKINE & CAM ANTAGONISTS	Rinvoq (all formulations); Olumiant tablet	X	
FACTOR DEFICIENCY PRODUCTS	Altuviiiio kit	X	
GENITAL WARTS & ACTINIC KERATOSIS AGENTS	fluorouracil cream	X	

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
GI ULCER THERAPIES	Carafate suspension	X	
	cimetidine suspension; sucralfate suspension		X
GROWTH HORMONE	Skytrofa injection	X	
	Nutropin injection		X
HEREDITARY ANGIOEDEMA	Beriner kit; Haegarda kit; icatibant injection	X	
HYPOGLYCEMICS, INSULINS AND RELATED AGENTS	Levemir (all formulations)		X
HYPOGLYCEMICS, SGLT2	Synjardy XR tablet; Glyxambi tablet; Trijardy XR tablet	X	
	Invokana tablet; Invokamet tablet		X
IBS/SBS/SELECTED GI AGENTS	Linzess (72 mcg) capsule; lubiprostone capsule; Trulance tablet	X	
	Amitiza capsule		X
LIPOTROPICS, OTHER (NON- STATINS)	colestipol granule; colestipol packet; fenofibrate capsule; fenofibric acid capsule	X	
	Praluent injection		X
MULTIPLE SCLEROSIS AGENTS	Gilenya capsule; Avonex injection		X
OPHTHALMIC, DRY EYE AGENTS	Xiidra drop	X	
OPHTHALMIC, GLAUCOMA AGENTS	brimonidine/timolol drop (generic Combigan); dorzolamide/timolol droperette;		X
OTIC ANTIBIOTICS	fluocinolone oil drop	X	
PARATHYROID AGENTS	cinacalcet tablet	X	
	Rocaltrol solution		X

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 22, 2024
PDL Changes Effective Date: January 1, 2025



PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
POTASSIUM REMOVING AGENTS	SPS suspension	X	
SEDATIVE HYPNOTICS	eszopiclone tablet; ramelteon tablet	X	
	flurazepam capsule; zolpidem capsule		X
STEROIDS (TOPICAL) LOW POTENCY	alclometasone cream/ointment; Derma-Smoothe-FS oil	X	
STEROIDS (TOPICAL) MEDIUM POTENCY	fluticasone cream/ointment; mometasone solution	X	
STEROIDS (TOPICAL) HIGH POTENCY	betamethasone dipropionate augmented cream/ augmented lotion/ointment; fluocinonide cream/emollient cream/gel/ointment/solution	X	
	amcinonide cream; triamcinolone aerosol		X
STEROIDS (TOPICAL) VERY HIGH POTENCY	clobetasol emollient cream/foam/gel/solution	X	
STIMULANTS AND RELATED AGENTS	methylphenidate solution; Qelbree capsule; Vyvanse capsule; Xyrem solution	X	
ULCERATIVE COLITIS and CROHNS AGENTS	Lialda DR tablet; mesalamine ER capsule (generic Apriso ER		X
UREA CYCLE DISORDERS*	Carbaglu dispersible tablet	X	